Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1652046

registered interest
date	11/07/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Economic Situation: Patents
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, whether her Department had discussions with its counterparts in the EU on the impact of standard essential patents on the economies of the (a) UK and (b) EU in the period between 1 January 2022 and 30 June 2023; and if she will make a statement.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193373
answer	answer is ministerial correction date of answer 21/07/2023 answer text <p>The Government believes that Standard Essential Patents (SEPs) will be of growing importance to the UK economy.</p><p> </p><p>In August 2022, the Government published a Summary of Responses relating to its call for views on SEPs and innovation, and more recently in July 2023 the Intellectual Property Office published findings following a questionnaire aimed at SMEs relating to their experiences around licensing of SEPs. During the Government’s ongoing policy development, it has engaged with relevant industry and international partners, including the EU, and will continue to do so on areas of mutual interest.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/07/2023 10:01:37 answering member 4020 label Biography information for George Freeman
tabling member	4124 label Biography information for Chi Onwurah

1652047

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Arthritis and Musculoskeletal Disorders: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has taken recent steps to help increase (a) public and (b) private research into treatments for (i) arthritis and (ii) musculoskeletal conditions.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193374
answer	answer is ministerial correction date of answer 13/07/2023 answer text <p>The Department, through the National Institute for Health and Care Research (NIHR), has awarded more than £100 million in funding and support for musculoskeletal conditions and arthritis research in the last five years.</p><p>The NIHR welcomes funding applications for research into any aspect of human health, including research into musculoskeletal conditions and arthritis. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. Therefore, future spend on arthritis and musculoskeletal research is undetermined.</p><p>In 2021/22 alone, NIHR infrastructure has supported over 900 studies and trials into musculoskeletal conditions. Six of the NIHR Biomedical Research Centres (BRCs) have musculoskeletal disorders as a research theme. For example, the Leeds BRC aims to improve treatment for osteoarthritis and to prevent disease and disability in immune-mediated diseases; this includes a work stream on non-surgical treatments for osteoarthritis. NIHR, in collaboration with Versus Arthritis, also funds a dedicated UK Musculoskeletal Translational Research Collaboration (UK MSK TRC). The UK MSK TRC aligns investment in musculoskeletal translational research, creating a United Kingdom-wide ambition and focus to drive cutting-edge translational research, in order to improve outcomes for patients.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/07/2023 16:30:34 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1652048

registered interest
date	11/07/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Mathematics: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, pursuant to the Answer of 30 June 2023 to Question 190871 on Mathematics: Research, whether the £124 million includes money spent as part of the Additional Funding Programme for Mathematic Sciences in the 2020-21 and 2022-23 financial years.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193375
answer	answer is ministerial correction date of answer 21/07/2023 answer text <p>The £124 million committed to the Additional Funding Programme for Mathematic Sciences covers the financial years 2020/21 to 2028/29. This is in addition to UKRI’s core funding for mathematical sciences of around £25-30 million per annum.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/07/2023 10:00:54 answering member 4020 label Biography information for George Freeman
tabling member	4124 label Biography information for Chi Onwurah

1652049

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made in implementing the recommendations of the Commercial clinical trials in the UK: the Lord O’Shaughnessy review, published 25 May 2023.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193376
answer	answer is ministerial correction date of answer 14/07/2023 answer text <p>On 26 May the Government published its initial response to the Lord O’Shaughnessy review into commercial clinical trials in the United Kingdom. This welcomed all recommendations in principle and made five headline commitments. A fuller response on all the recommendations and an implementation update and longer-term plan will be published in the autumn.</p> answering member constituency Colchester answering member printed Will Quince question first answered 14/07/2023 13:45:05 answering member 4423 label Biography information for Will Quince
tabling member	4124 label Biography information for Chi Onwurah

1652050

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much Government funding was allocated to dementia research in each of the last five years.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193377
answer	answer is ministerial correction date of answer 18/07/2023 answer text <p>Government responsibility for delivering dementia research is shared between the Department for Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation, mainly by the Medical Research Council (MRC) and Economic and Social Research Council (ESRC).</p><p>The amount spent by these funders, excluding the Biotechnology and Biological Sciences Research Council, the Engineering &amp; Physical Sciences Research Council and Innovate UK, on dementia research for the last five years of available data is shown in the table below.</p><table><tbody><tr><td><p>Year</p></td><td><p>2017/18</p></td><td><p>2018/19</p></td><td><p>2019/20</p></td><td><p>2020/21</p></td><td><p>2021/22</p></td></tr><tr><td><p>NIHR</p></td><td><p>£43 million</p></td><td><p>£31.6 million</p></td><td><p>£29 million</p></td><td><p>£21.9 million</p></td><td><p>£31.3 million</p></td></tr><tr><td><p>MRC</p></td><td><p>£34.9 million</p></td><td><p>£56.5 million</p></td><td><p>£44 million</p></td><td><p>£46.9 million</p></td><td><p>£41.6 million</p></td></tr><tr><td><p>ESRC</p></td><td><p>£4 million</p></td><td><p>£7.4 million</p></td><td><p>£5.9 million</p></td><td><p>£8 million</p></td><td><p>£7.4 million</p></td></tr><tr><td><p>Total</p></td><td><p>£81.9 million</p></td><td><p>£95.5 million</p></td><td><p>£78.9 million</p></td><td><p>£76.8 million</p></td><td><p>£80.3 million</p></td></tr></tbody></table><p> </p><p>Spend for dementia research is calculated retrospectively and is usually finalised around eight months after the end of the financial year. Therefore, 2021/22 is the most recent year we have full data for.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 18/07/2023 10:10:19 answering member 4527 label Biography information for Helen Whately
tabling member	4124 label Biography information for Chi Onwurah

1652051

registered interest
date	11/07/2023
answering body	Department for Energy Security and Net Zero
answering dept id	215
answering dept short name	Energy Security and Net Zero
answering dept sort name	Energy Security and Net Zero
hansard heading	Euratom
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Energy Security and Net Zero, whether he has made a recent assessment of the potential merits of seeking association with the Euratom Research and Training Programme.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193378
answer	answer is ministerial correction date of answer 17/07/2023 answer text <p>Association to Euratom R&amp;T would need to provide value to the UK’s fusion sector, nuclear researchers and taxpayers. As such it must reflect the lasting impact of two years of delay when UK researchers and businesses were not able to engage in the Euratom R&amp;T Programme or compete for contracts at ITER.</p><p> </p><p>We have been working with the UK Atomic Energy Authority to design an ambitious expansion of activity to secure delivery of the UK’s Fusion Strategy, including support for public and private sector projects. If we cannot agree terms for association these new measures will be implemented.</p> answering member constituency West Aberdeenshire and Kincardine answering member printed Andrew Bowie grouped question UIN 193633 question first answered 17/07/2023 06:28:50 answering member 4601 label Biography information for Andrew Bowie
tabling member	4124 label Biography information for Chi Onwurah

1652109

registered interest
date	11/07/2023
answering body	Department for Levelling Up, Housing and Communities
answering dept id	211
answering dept short name	Levelling Up, Housing and Communities
answering dept sort name	Levelling Up, Housing and Communities
hansard heading	Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Levelling Up, Housing and Communities, if he will make an estimate of the potential changes in the level of (a) employment and (b) private sector co-investment in R and D projects since the end of European Regional Development Fund support for innovation.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193394
answer	answer is ministerial correction date of answer 17/07/2023 answer text <p>The UK Shared Prosperity Fund (UKSPF) is a successor, and not a replacement, to the former European Social Fund and European Regional Development Fund.</p><p>Each place was tasked with working with local partners - including businesses and education and innovation providers - to develop an investment plan. Places could choose from a range of interventions, including investment in research and development (R&amp;D). It is for places to decide how they use their allocation for R&amp;D, and this will depend on locally identified priorities.</p><p>Each place was also strongly encouraged to consider match funding from the private, public and third sectors and leverage options to maximise fund impact.</p> answering member constituency Bishop Auckland answering member printed Dehenna Davison question first answered 17/07/2023 12:25:07 answering member 4737 label Biography information for Dehenna Davison
tabling member	4124 label Biography information for Chi Onwurah

1652110

registered interest
date	11/07/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Innovation: Science
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, what comparative assessment she has made of the relative advantage to (a) researchers and (b) manufacturers of (i) gene therapies and (ii) other scientific innovations of location in (A) the UK and (B) other European countries.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193395
answer	answer is ministerial correction date of answer 21/07/2023 answer text <p>The UK is home to 4 of the world’s top 10 universities and a $1 trilllion technology sector. Together 8 of our university towns, are home to more billion-dollar unicorn start-ups than France and Germany combined.</p><p> </p><p>The science and technology framework, builds on the Innovation Strategy, with around £500 million new and existing funding. This includes a £50 million uplift to World Class Labs funding to help UK researchers access the best labs and equipment they need to keep producing world-class science.</p><p> </p><p>The Government supports the NHS in R&amp;D of advanced therapy medicinal products, including gene therapies, through the Advanced Therapy Treatment Centre network, hosted by the Cell and Gene Therapy Catapult. The Catapult, head-quartered in Stevenage, is at the centre of the third largest cluster of cell and gene therapy companies in the world.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/07/2023 09:59:31 answering member 4020 label Biography information for George Freeman
tabling member	4124 label Biography information for Chi Onwurah

1652112

registered interest
date	11/07/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, with reference to her speech at the Creating a Scientific Superpower Conference on 28 June 2023, what the substantial progress is that her Department has made towards realising its ambitious Life Sciences Vision.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193396
answer	answer is ministerial correction date of answer 21/07/2023 answer text <p>In the two years since its publication, substantial progress has been made in delivering the ambition of the Vision, including the publication of the Genome UK Implementation Plan, alongside £175 million for cutting edge genomic research.</p><p> </p><p>Most recently, on 26 May, we announced a £650 million policy package that will support several key areas of the life sciences sector, including clinical trials, biomanufacturing, and skills, and drive economic growth. This month, we have also signed a landmark agreement with BioNTech SE which will provide up to 10,000 UK patients with innovative precision cancer immunotherapies by 2030.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/07/2023 09:56:19 answering member 4020 label Biography information for George Freeman
tabling member	4124 label Biography information for Chi Onwurah

1652113

registered interest
date	11/07/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Technology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, with reference to her speech at the Creating a Scientific Superpower Conference on 28 June 2023, what steps she is taking to help ensure that (a) one-time gene therapies and (b) other revolutionary emerging technologies are available in the UK.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	193397
answer	answer is ministerial correction date of answer 21/07/2023 answer text <p>The Government supports the NHS in R&amp;D of advanced therapy medicinal products, including gene therapies, through the Advanced Therapy Treatment Centre network, hosted by the Cell and Gene Therapy Catapult. The Catapult, head-quartered in Stevenage, is at the centre of the third largest cluster of cell and gene therapy companies in the world.</p><p> </p><p>Additionally, the Science and Technology Framework, published in March identifies the critical technologies that are crucial to the UK. It also details the steps required to build upon our world class research base to attract investment, grow UK companies and talent, and innovate successfully and safely.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/07/2023 09:49:28 answering member 4020 label Biography information for George Freeman
tabling member	4124 label Biography information for Chi Onwurah